In ovarian cancers, immunohistochemical examination of surgically resected tumors has demonstrated that IDO is prevalent in ~56 % of ovarian tumors and correlates with a reduced antitumor immune response [42]. This evidence concerns the gene IDO1 and ovarian carcinoma.